Researchers will evaluate the potential of a therapeutic agent to reduce the frequency and severity of acute stress disorder and post-traumatic stress disorder, according to an Oct. 6 news release.
The proposed trial will examine the safety and efficacy of ACER-801, or osanetant, in reducing acute stress response symptoms, posttraumatic stress disorder symptoms, and behavioral changes among patients after a motor vehicle collision.
“Historically, we have been able to provide emergency care to address immediate and long-term problems after visible wounds using tools such as sutures and antibiotics. However, we still have nothing to offer trauma survivors, whether in the emergency department or on the battlefield immediately after trauma, to prevent the development of ‘invisible wounds,'” said Samuel McLean, MD, MPH, professor of psychiatry and emergency medicine and director of the Institute for Trauma Recovery at the UNC School of Medicine.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
